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Background: Epithelial to mesenchymal transition (EMT) is under discussion as a potential mechanism of
small airway remodelling in COPD. In bronchial epithelium of COPD and smokers markers of EMT were
described. In vitro, EMT may be reproduced by exposing well-differentiated human bronchial epithelial
cells (WD-HBEC) to cigarette smoke extract (CSE). EMT may be mitigated by an increase in cellular cAMP.
Objective: This study explored the effects of roflumilast N-oxide, a PDE4 inhibitor on CSE-induced EMT in
WD-HBEC and in primary bronchial epithelial cells from smokers and COPD in vitro.
Methods: WD-HBEC from normal donors were stimulated with CSE (2.5%) for 72 h in presence of
roflumilast N-oxide (2 nM or 1 mM) or vehicle. mRNA and protein of EMT markers aSMA, vimentin,
collagen-1, E-cadherin, ZO-1, KRT5 as well as NOX4 were quantified by real-time quantitative PCR or
protein array, respectively. Phosphorylated and total ERK1/2 and Smad3 were assessed by protein array.
cAMP and TGFb1 were measured by ELISA. Reactive oxygen species (ROS) were determined by DCF
fluorescence, after 30 min CSE (2.5%). Apoptosis was measured with Annexin V/PI labelling. In some
experiments, EMT markers were determined in monolayers of bronchial epithelial cells from smokers,
COPD versus controls.
Results: Roflumilast N-oxide protected from CSE-induced EMT in WD-HBEC. The PDE4 inhibitor reversed
both the increase in mesenchymal and the loss in epithelial EMT markers. Roflumilast N-oxide restored
the loss in cellular cAMP following CSE, reduced ROS, NOX4 expression, the increase in TGFb1 release,
phospho ERK1/2 and Smad3. The PDE4 inhibitor partly protected from the increment in apoptosis with
CSE. Finally the PDE4 inhibitor decreased mesenchymal yet increased epithelial phenotype markers in
HBEC of COPD and smokers.
Conclusions: Roflumilast N-oxide may mitigate epithelialemesenchymal transition in bronchial epithe-
lial cells in vitro.
 2014 Published by Elsevier Ltd.106
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monary Pharmacology & The1. Introduction
Chronic obstructive pulmonary disease (COPD) is a preventable
and treatable lung disease characterized by airflow limitation that
is progressive and not fully reversible. The airflow limitation is the
consequence of abnormal chronic inflammation of the lungs and
manifests as small airway disease (obstructive bronchiolitis) and117
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rapeutics (2014), http://dx.doi.org/10.1016/j.pupt.2014.02.001



































































































































YPUPT1357_proof ■ 13 February 2014 ■ 2/11parenchymal destruction (emphysema). Small airways (smaller
than 2 mm of internal diameter) are responsible of the 60% of the
total resistance in COPD [1e4]. Cigarette smoking is the most
commonly recognized risk factor for COPD, increasing and
perpetuating lung inflammation and remodelling. As part of lung
remodelling, airwaywall thickening, peribronchial fibrosis, luminal
inflammatory exudates and the consequent airway narrowing in
small airways are correlated with disease severity [5]. Recent
studies have shown that proliferation of bronchial smooth muscle
cells and bronchial accumulation of myofibroblasts critically de-
termines small airway narrowing in COPD [6,7]. Myofibroblasts
may have different origins such as resident bronchial smooth
muscle or fibroblast to myofibroblast transition, epithelial to
mesenchymal transition (EMT) or the recruitment of fibrocytes [8].
Small airway disease likely elicited by cigarette smoking has
been considered as a therapeutic target in COPD [6]. Besides
inflammation, cigarette smoke promotes lung fibroblasts to myo-
fibroblast transformation [9e11]. Furthermore, recent studies
indicate that EMT may be induced by cigarette smoke in bronchial
epithelial cells contributing to small bronchial narrowing in COPD
[12e14]. In this regard, we recently showed that EMT is present in
primary bronchial epithelial cells from small bronchi of smokers
and COPD patients and induced by cigarette smoke [12]. EMT may
be controlled by a number of intracellular pathways such as the
generation of reactive oxygen species (ROS), activation of mitogen-
activated protein kinase (MAPK) and Smad signalling, as well as by
the increase of adenosine 30,50-cyclic monophosphate (cAMP)
degrading phosphodiesterase (PDE) 4 [15,16]. The PDE4 family is
composed of four subtypes (PDE4A-D) encoded by different genes
that by alternative splicing are expressed as multiple variants
differing in their N-terminal domains [17,18]. PDE4 plays a role in
almost all cells related to COPD including lung fibroblasts and
airway epithelial cells [19]. In particular, inhibition of PDE4 by
rolipram reduced epithelial to mesenchymal transition (EMT) sec-
ondary to TGF-b1 in the alveolar epithelial cell line A549 [16].
The PDE4 inhibitor roflumilast has been approved to reduce the
risk of acute exacerbations and improve lung function in patients
with severe COPD associated with chronic bronchitis and a history of
exacerbations [20,21]. While anti-inflammatory effects are discussed
as key to understand the clinical efficacy of roflumilast [21,22] in vivo
and in vitro studies indicate that the PDE4 inhibitor could also in-
fluence lung architectural remodelling. For example roflumilast
mitigates airspace enlargement in mice exposed to tobacco smoke
over several months or alleviates bleomycin-induced lung fibrotic
remodelling in therapeutic protocols in vivo. In cell culture experi-
ments, roflumilast N-oxide and other PDE4 inhibitors were shown to
inhibit myofibroblast transition, migration or proliferation of human
lung fibroblasts [23e25]. However, whether roflumilast curbs ciga-
rette smoke-induced EMT in well-differentiated human bronchial
epithelial cells in vitro has not previously been investigated.
The current study was designed to explore the effects of the
PDE4 inhibitor roflumilast N-oxide on EMT induced by cigarette
smoke in well-differentiated human bronchial epithelial cells
(HBECs) of small bronchi in vitro. We also analysed the effects of
roflumilast N-oxide on mesenchymal and epithelial markers of
primary HBECs from smokers and COPD patients. Roflumilast
N-oxide is the active metabolite of roflumilast largely accounting
for its clinical efficacy in man [19].
2. Materials and methods
2.1. Patients
A total of 10 non-smoker controls, 8 smokers without COPD and
9 smokers with COPD were included in the study. COPD patientsPlease cite this article in press as: Milara J, et al., Roflumilast N-oxide
cigarette smoke in smokers with COPD, Pulmonary Pharmacology & Thewere diagnosed according to the GOLD guidelines [26]. All lung
tissues studied in this work were taken from uninvolved lung tissue
during lobectomy/wedge resection for malignant lesions in the
thoracic Surgery and Respiratory Unit, University General Hospital
Consortium, Valencia, Spain, between 2009 and 2012. Samples of
distal lung, located as far away as possible from the tumour, were
chosen for the study. All pulmonary function tests were performed
within 3 months before surgery. Clinical data of all patients were
examined for possible co-morbidity and medication use. Inclusion
criteria were defined as: non-smokers, smokers without and with
COPD (free of symptoms of upper respiratory tract infections, none
received antibiotics perioperatively). After selection based on lung
function, all lung tissue samples used for the study were checked
histologically by using the following exclusion criteria: (1) presence
of tumour, (2) presence of post-stenotic pneumonia, and (3) fibrosis
of lung parenchyma. The protocol was approved by the local
research and independent ethics committee of the University
General Hospital of Valencia. Informed written consent was ob-
tained from each participant.
2.2. Isolation of primary bronchial epithelial cells and incubations
with roflumilast N-oxide
Isolation of human bronchial epithelial cells from small bronchi
was performed as previously outlined [27]. Small pieces of human
bronchi (0.5e1 mm internal diameter) were excised from micro-
scopically normal lung areas, carefully dissected free from lung
parenchyma and plated on collagen-coated culture dishes (10 mg/
cm2 rat type I collagen (Sigma Aldrich, Madrid, Spain)) in bronchial
epithelial growth medium (BEGM, comprising bronchial epithelial
basal medium (BEBM) supplemented with bovine pituitary extract
(52 mg/ml), hydrocortisone (0.5 mg/ml), human recombinant
epidermal growth factor (EGF) (25 ng/ml), epinephrine (0.5 mg/ml),
transferrin (10 mg/ml), insulin (5 mg/ml), retinoic acid (50 nM),
triiodo-L-thyronine (6.5 ng/ml), gentamycin (40 mg/ml), ampho-
tericin B (50 ng/ml), and bovine serum albumin (1.5 mg/ml). Small
bronchi were orientedwith the epithelial layer to be in contact with
the culture plate. After a period of about 7e12 days, bronchial
epithelial cells were observed around bronchi and used to measure
mRNA and protein expression of epithelial and mesenchymal
markers of different subjects in presence or absence of roflumilast
N-oxide (2 nM) or vehicle (0.1% DMSO) for 24 h. The identity of the
monolayer as bronchial epithelial cells was affirmed by morpho-
logical criteria and immunofluorescence for cytokeratin 5 (KRT5) as
well as the later in vitro differentiation in aireliquid interface as
pseudo-stratified bronchial epithelium with basal cells, ciliated
cells, columnar and goblet cells. Cell viability was assessed by vital
trypan blue exclusion analysis using the Countness automated cell
counter (Life technologies, Madrid, Spain). Cell viability was >98%
in all cell cultures tested in this work. Roflumilast N-oxide (Takeda)
was diluted from a 10 mM stock in DMSO to the final concentration
of 2 nM in 0.1% DMSO. A concentration of 2 nM of roflumilast
N-oxide corresponds to plasma concentrations (unbound to plasma
proteins) of this active metabolite of roflumilast maintained over
the 24 h dosing interval following repeated dosing of roflumilast at
its approved clinical dose of 500 mg once daily per os [19].
2.3. Culture of aireliquid interface bronchial epithelial cells
Differentiated HBECs for in vitro experiments were obtained
from non-smoking subjects. Primary HBECs were trypsinized and
subpassaged on 12-well polyester Transwell inserts (Millipore) at
1.5  105 cells per insert. Cells were left for 7 days submerged in
BEGM/DMEM (1:1) culture medium. From day 7 the aireliquid
interface culture was initiated by removing the medium from theinhibits bronchial epithelial to mesenchymal transition induced by
rapeutics (2014), http://dx.doi.org/10.1016/j.pupt.2014.02.001



































































































































YPUPT1357_proof ■ 13 February 2014 ■ 3/11upper well leaving the apical side of the cells exposed to air and
changing the final epidermal growth factor (EGF) concentration to
0.5 ng/ml (differentiation medium). In general aireliquid interface
cultures were pursued until about 80e90% of cells were ciliated by
microscopic inspection (about 3e4 weeks after initiation) before
experiments were commenced [27]. Cells were maintained at 37 C
with 5% CO2 and medium changed every other day. At this stage a
pseudo-stratified bronchial epithelium comprising basal cells, cili-
ated cells and goblet cells was obtained and considered as
“differentiated”.
2.4. Preparation of cigarette smoke extract
Cigarette smoke extracts (CSE) were obtained as previously
outlined [28,29]. Briefly, the smoke of a research cigarette (2R4F;
Tobacco Health Research, University of Kentucky, KY, USA) was
generated by a respiratory pump (Apparatus Rodent Respirator
680; Harvard, Germany) through a puffing mechanism related to
the human smoking pattern (3 puff/min; 1 puff 35 ml; each puff of
2 s duration with 0.5 cm above the filter) and was bubbled into a
flask containing 25 ml of pre-warmed (37 C) BEGM/DMEM me-
dium. The CSE solution was sterilized by filtration through a 0.22-
mm cellulose acetate sterilizing system (Corning, NY). The resultant
CSE solution was considered to be 100% CSE and was used for ex-
periments within 30 min of preparation. CSE 10% corresponds
approximately to the exposure associated with smoking two packs
per day [30]. The quality of the prepared CSE solution was assessed
based on the absorbance at 320 nm, which is the specific absorp-
tion wavelength of peroxynitrite. Stock solutions with an absor-
bance value of 3.0  0.1 were used.
2.5. In vitro stimulation of differentiated HBECs
For in vitro studies, differentiated HBEC were stimulated with
CSE 2.5% for the indicated times (in general 72 h unless indicated
otherwise), replacing culture medium and stimulus every 24 h.
Roflumilast N-oxide (2 nM and 1 mM; RNO) or vehicle (0.1% DMSO)
was added 30 min before stimulus. Both test compounds and CSE
were added to the basolateral media (500 ml) and at the apical
surface (25 ml). As manipulations at the apical surface may affect
pseudo-stratified epithelium, all incubations with vehicle controls
were run under identical conditions as with CSE and test com-
pounds (for example identical volumes of medium were added to
the apical surface throughout all conditions, same for the baso-
lateral compartment). In control experiments where vehicle/me-
dium (for test compounds/CSE) were added to the apical surface of
differentiated HBECs over a maximum of 3 days (including daily
replacement procedures, as indicated) the number of ciliated cells
and expression of cilia markers were found to be not different from
cultures of differentiated human bronchial epithelial cells in the
absence of the manipulations at the apical surface.
As previously shown by us and others, the in vitro incubation of
well-differentiated human bronchial epithelial cells with CSE re-
capitulates changes in markers of EMT as found in bronchial
epithelium of smokers with and without COPD [12,13,15,31] and
may therefore be useful to dissect molecular mechanisms involved
in this pathological process.
2.6. Real-time RT-PCR
Total RNA was isolated from primary HBEC and differentiated
bronchial epithelial cells in aireliquid interface by using TriPure
Isolation Reagent (Roche, Indianapolis, USA). The integrity of the
extracted RNA was confirmed with Bioanalyzer 2100 (Agilent, Palo
Alto, CA, USA). The reverse transcription was performed in 300 ngPlease cite this article in press as: Milara J, et al., Roflumilast N-oxide
cigarette smoke in smokers with COPD, Pulmonary Pharmacology & Theof total RNA with TaqMan reverse transcription reagents kit
(Applied Biosystems, PerkineElmer Corporation, CA, USA). cDNA
was amplified with specific primers and probes predesigned by
Applied Biosystems for a-SMA (Hs00559403_m1), a1(I)-collagen
(collagen type I; cat. n: Hs00164004_m1), vimentin (cat. n: Hs
00958116_m1), E-cadherin (cat. n: Hs01023894_m1), zona
occludens-1 (ZO-1; cat. n: Hs01551861_m1), KRT5 (cat. n:
Hs00361185_m1) and NOX4 (cat. n: Hs00276431_m1), and
GAPDH (cat. n: 4352339E) as a housekeeping gene in a 7900HT
Fast Real-Time PCR System (Applied Biosystem) using Universal
Master Mix (Applied Biosystems). Relative expression of these
different transcripts was determined with the 2DDCt method using
GAPDH as endogenous control (Applied Biosystems; 4352339E)
and normalized to non-smoker or control group.
2.7. Protein array
Protein expression in primary isolated HBEC from non-smokers,
smokers and COPD patients and in vitro differentiated HBECs was
analysed with Zeptosens (Division of Bayer [Schweiz], Switzerland)
protein array technology as previously outlined [12]. Cells were
lysed with CeLyA Lysis Buffer CLB1 (Zeptosens, Division of Bayer
(Schweiz), Switzerland), incubated during 30 min at room tem-
perature and centrifuged (5 min at 15,000 g) in order to remove
debris. The supernatants were collected, frozen in liquid nitrogen
and stored at 80 C.
Protein concentration was determined using a Bradford-
Coomassie Plus Assay Kit (Pierce). Protein content was adjusted to
2 mg/ml and samples were subsequently diluted using spotting
buffer (PBS þ 10% DMSO þ 5% Glycerol) to obtain four different
protein concentrations corresponding to 100, 75, 50 and 25%
(0.2 mg/ml, 0.15 mg/ml, 0.1 mg/ml and 0.05 mg/ml) of the primary
spotting solution. For each of these four dilutions, duplicate spots
were arrayed onto ZeptoMARK chips (Zeptosens) as single sample
droplets of about 400 pl, using a Micro Pipetting System Nano-
plotterTM (NP2.1, GeSiM, Groberkmannsdorf, Germany). After spot-
ting, the chipswere dried for 1 h at 37 C and blocked in an ultrasonic
nebulizer (ZeptoFOG Blocking Station, Zeptosens) with CeLyA
Blocking Buffer (BB1, Zeptosens). Blocked chips were rinsed with
water (Milli-Q quality), dried and stored at 4 C in the dark until
further use. Antibody incubations were done in CeLyA Assay Buffer
CAB1 based on BSA according to standard protocols (Zeptosens). The
chips were assembled with chip fluidic structures in a ChipCARRIER
(Zeptosens) and were incubated with primary antibodies (1:500
dilution in CAB1) overnight at room temperature. After rinsing the
system with assay buffer, the chips were incubated with secondary
fluorescence-labelledlabelled anti-species antibodies (Zenon Alexa
Fluor 647 Rabbit IgG and mouse IgG LabellingLabelling Kit (cat. n:
Z25308 and Z25008, Molecular Probes) (1:500 dilution in CAB1) for
1 h at room temperature. After rinsing the system with assay buffer
to remove the excess secondary antibody, the fluorescence readout
was performedwith the ZeptoREADER instrument (Zeptosens), at an
extinction wavelength of 635 nm and an emission wavelength of
670 nm. The fluorescence signal was integrated over a period of 1e
10 s, depending on the signal intensity. Array images were stored as
16-bit TIFF files and analysed with the ZeptoView Pro software
package (version 2.0, Zeptosens). Relative intensities were obtained
by plotting net spot intensities against protein concentrations of the
spotted samples determined by a Bradford assay as described above.
Briefly, the eight data points for each sample were fitted using a
weighted linear least squares fit [33]. The relative intensity was then
interpolated at the median protein concentration. The SD calculated
from the fit is indicative for the linearity of the dilution series. Sub-
sequently the data were renormalized to correct for small variations
in protein content using mouse anti-human b-actin (cat n: A1978;inhibits bronchial epithelial to mesenchymal transition induced by
rapeutics (2014), http://dx.doi.org/10.1016/j.pupt.2014.02.001



































































































































YPUPT1357_proof ■ 13 February 2014 ■ 4/11Sigma), total rabbit anti-human ERK1/2 (1:1000) antibody (mono-
clonal antibody; Cell Signalling, Boston, Massachusetts, USA; cata-
logue no. 4695) or total rabbit anti-human Smad3 (cat n: 566414;
Calbiochem) as internal standards. Primary antibodies used were
mouse anti-human a-SMA (cat. n: A5228; Sigma), rabbit anti-
human collagen type I antibody (cat. n: PA1-26204; Affinity Bio-
reagents), mouse anti-human vimentin (cat. n: V6389; Sigma),
mouse anti-human E-cadherin (cat. n: CM1681; ECM BioScience),
rabbit anti-human ZO-1 (cat. n: ab59720; Abcam), mouse anti-
human phospho-ERK1/2 (cat. n: M-9692; Sigma), rabbit anti-
human phospho-Smad3 (cat. n: PS1023; Calbiochem), and NOX4
(cat. n: NB110-58849; Novus Biologicals).
2.8. DCF fluorescence measurement of reactive oxygen species
20, 70-dichlorodihydrofluorescein diacetate (H2DCF-DA,Molecular
Probes, UK) is a cell-permeable compound that following intracel-
lular ester hydrolysis is oxidized to fluorescent 20, 70-dichloro-
fluorescein (DCF) by O2L and H2O2, and can therefore be used to
monitor intracellular generation of ROS [34]. To quantify ROS levels,
differentiated human bronchial epithelial cells were washed twice
with PBS and incubated for 30 minwith 50 mMH2DCF-DA diluted in
Opti-MEM in presence of roflumilast N-oxide or vehicle. Then, cells
were again washed twice with PBS to remove remaining H2DCF-DA
and stimulated with CSE for 30 min in presence of roflumilast N-
oxide or vehicle. Five randomly selected fields per condition were
measured for fluorescent intensity using an epifluorescence micro-
scope (Nikon Eclipse TE 200, Tokio, Japan) with filter set for FITC.
Subsequent image capture and analysis was performed using Met-
afluor 5.0 software (Analytical Technologies, US). Results were
expressed as DCF fluorescence in relative fluorescence units.
2.9. Enzyme-linked immunosorbent assays for TGF-b1 and cAMP
Quantitative ELISA for TGF-b1 was performedwith supernatants
of differentiated HBECs following 72 h of stimulation with CSE in
presence or absence of roflumilast N-oxide using quantikine hu-
manTGF-b1 immunoassay (R&D Systems; catalogue no. 891124). To
measure latent complexes of TGF-b1, activation was accomplished
by acid treatment. Therefore, 50 ml of cell culture supernatants were
treated with 10 ml of 1 M HCl, incubated for 10 min, and then
neutralised with 10 ml of 1.2 M NaOH/0.5 M HEPES.
Intracellular cAMP content was determined in differentiated
HBEC as previously outlined [35]. Following incubations with CSE
in presence or absence of roflumilast N-oxide as indicated, culture
medium was removed and cells were washed with phosphate-
buffered saline (PBS). Then, cells were lysed and the intracellular
cAMP content was determined with the cAMP Biotrak Enzyme
Immunoassay (EIA) system according to manufacturer’s in-
structions (Amersham, UK). Results were expressed as fmol cAMP
per mg of protein (per insert).
2.10. Apoptosis assay
To determine apoptosis/necrosis, phosphatidylserine flipping
from the inside to the outside surface of the plasma membrane was
examined by the annexin V assay according to the manufacturer’s
instructions (Roche, Applied Science, UK). Differentiated HBECs
were incubated with CSE (2.5%) in the presence of roflumilast
N-oxide (2 nM or 1 mM) or vehicle for 72 h. In separate experiments,
apoptosis/necrosis in primary HBECs from healthy, smokers and
COPD patients was also evaluated. At the end of the incubations
cells were washed three times with phosphate-buffered saline
(PBS) and then labelled in situwith 5 ml each of annexin V-FITC and
propidium iodide (PI) for 15min at room temperature as previouslyPlease cite this article in press as: Milara J, et al., Roflumilast N-oxide
cigarette smoke in smokers with COPD, Pulmonary Pharmacology & Theoutlined [32]. Six randomly selected fields were counted for fluo-
rescent cells using an epifluorescence microscopy (Spectramaster
System, Perkin Elmer, Life Sciences, Cambridge, UK) with dual filter
set for FITC and rhodamine. Subsequent image capture and analysis
was performed using Metafluor 5.0 software (Analytical Tech-
nologies, US). Apoptotic (Annexin Vþ / PI) and necrotic (Annexin
V þ / PI þ) cells were counted and expressed as % of total cells
(counted by phase contrast microscopy of the same field.
2.11. Statistics
Statistical analysis of results was carried out by parametric or
non-parametric analysis as appropriate. Data from parametric
analysis (Figs. 1e4) were expressed as mean  SD. Data of in vitro
mechanistic experiments in differentiated HBECs from non-smoker
patients were performed by Student’s t-test, one-way or two-way
analysis of variance followed by Bonferroni post hoc test. Data
from non-parametric analysis (Figs. 5e7) was expressed as median,
interquartile range and minimum and maximum values. Manne
Whitney U test or KruskaleWallis test followed by Dunn’s post hoc
test for multiple comparisons were used to compare mesenchymal
and epithelial data from non-smokers, smokers and COPD patients.
Correlations were analysed using the Spearman (r) correlation
analysis. Significance was accepted when P < 0.05.
3. Results
3.1. Roflumilast N-oxide inhibits cigarette smoke-induced epithelial
to mesenchymal transition in differentiated HBECs
Differentiated HBECs were obtained from bronchial epithelial
cells of non-smokers following aireliquid interface culture. As
previously described [12], CSE at 2.5% increased gene and protein
expression of mesenchymal markers a-SMA, vimentin and collagen
type I (Fig. 1A and C) and decreased the expression of epithelial
markers E-cadherin, ZO-1 and KRT5 (Fig. 1B and D). Furthermore,
under phase contrast microscopy, differentiated HBEC exposed to
CSE adopted a flattened and elongated morphology characteristic
of a myofibroblast-like phenotype (Fig. 2). Incubation with roflu-
milast N-oxide at 1 mM (corresponding to complete and selective
inhibition of PDE4) and 2 nM (corresponding to about half-
maximum inhibition of PDE4 [19] and free plasma concentrations
in man following clinical dosing of roflumilast [36]) largely abol-
ished the increase of mesenchymal markers, reversed the loss of
epithelial markers induced by cigarette smoke and conserved the
epithelial cell phenotype (Fig. 1AeD and Fig. 2).
In other experiments effects of medium (72 h) or CSE (2.5% over
72 h) in the presence of roflumilast N-oxide (2 nM, 1 mM over 72 h)
or vehicle (0.1% DMSO) on apoptosis or necrosis (assessed by
Annexin V-FITC/PI labelling) of differentiated HBECs were explored.
Necrosis (Annexin Vþ / PIþ cells) was (invariably) almost absent. In
medium control cells apoptosis (Annexin Vþ / PI) was found in
17.5  3.7% of total cells that may reflect turnover in the differen-
tiated bronchial epithelial cell cultures. CSE about doubled
apoptosis to 35.3  2.62% of total cells and the increment was
partially prevented (by about 50%) in the additional presence of the
PDE4 inhibitor (to 26.1  1.2% at 2 nM and 25.3  1.8% at 1 mM of
roflumilast N-oxide (Fig. 2)).
3.2. Roflumilast N-oxide inhibits intracellular pathways involved in
cigarette smoke induced epithelial to mesenchymal transition in
differentiated HBECs
Exposure of well-differentiated human bronchial epithelial cells
to CSE impairs cellular cAMP content and enhances levels ofinhibits bronchial epithelial to mesenchymal transition induced by
rapeutics (2014), http://dx.doi.org/10.1016/j.pupt.2014.02.001
Fig. 1. Roflumilast N-oxide (RNO) inhibits epithelial to mesenchymal transition induced by cigarette smoke extract (CSE) in differentiated human bronchial epithelial cells (HBECs).
Differentiated HBECs were incubated with RNO (2 nM, 1 mM) for 30 min before CSE (2.5%) stimulation for 72 h (A, B) Total RNA and (C, D) protein were isolated for real-time PCR and
protein array Zeptosens analysis respectively. CSE-induced upregulation of (A) mRNA and (C) protein expression of mesenchymal markers a-SMA, vimentin and collagen type I (col
type I) was inhibited by RNO. CSE-induced downregulation of (B) mRNA and (D) protein expression of epithelial markers E-cadherin, ZO-1 and KRT5 was reversed by RNO. Data are
expressed as the ratio to GAPDH for mRNA levels and to b-actin for protein levels and normalized to the vehicle control group. Results are expressed as means  SD of n ¼ 3e4 (two
to four cell non-smoker population) experiments per condition. Two-way ANOVA followed by post hoc Bonferroni tests. *P < 0.05 related to solvent controls; #P < 0.05 related
to CSE.
Fig. 2. Roflumilast N-oxide (RNO) reduces apoptosis induced by cigarette smoke extract (CSE) in differentiated human bronchial epithelial cells (HBECs). Differentiated HBEC were
exposed to CSE (2.5%) over 72 h or medium (control) in the presence of RNO at 2 nM or 1 mM, or vehicle (0.1% DMSO) (30 min pre-incubation). CSE changes the morphology from
epithelial to mesenchymal with reduced cell-to-cell contact that was prevented by RNO (1 mM) (phase contrast light microscopy). Apoptosis/Necrosis were assessed by Annexin
V-FITC and propidium iodide (15 min) labeling. Annexin Vþ/PI- (apoptotic) and Annexin Vþ/PIþ (necrotic) cells were counted (epifluorescence microscope in a total of six fields per
condition) and results expressed as percentage of total cells. RNO partly reduced the CSE-induced increment in apoptosis. Results are the mean  SD of n ¼ 3 experiments from
three different patients. Scale bar: 50 mm.
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Please cite this article in press as: Milara J, et al., Roflumilast N-oxide inhibits bronchial epithelial to mesenchymal transition induced by
cigarette smoke in smokers with COPD, Pulmonary Pharmacology & Therapeutics (2014), http://dx.doi.org/10.1016/j.pupt.2014.02.001
Fig. 3. Roflumilast N-oxide (RNO) reversed a cigarette smoke extract (CSE)-induced decrease in cyclic adenosine monophosphate (cAMP) and increase in intracellular reactive
oxygen species (ROS) and NOX4 expression in differentiated human bronchial epithelial cells (HBECs). Differentiated HBECs were incubated with RNO (2 nM, 1 mM) for 30 min
before stimulation with CSE (2.5%) for (A, B, C) 72 h or (D, E) 30 min. (A) The loss in intracellular cAMP following CSE was prevented by RNO. (B, C) CSE-induced mRNA and protein
expression of NOX4, which were significantly inhibited by RNO. Data are expressed as the ratio to GAPDH for mRNA levels and to b-actin for protein levels and normalized to vehicle
control group. (D, E) RNO reduced ROS following CSE determined by means of DCF fluorescence intensity. (D) Representative images of positive DCF fluorescence in differentiated
HBECs. Scale bar: 10 mm. (B, C) Results are expressed as means  SD of n ¼ 3 (two to three cell non-smoker population) experiments per condition. Two-way ANOVA followed by
post hoc Bonferroni tests. *P < 0.05 related to solvent controls; #P < 0.05 related to CSE. RFU: relative fluorescence units.
















































































































YPUPT1357_proof ■ 13 February 2014 ■ 6/11oxidative stress and both are involved in EMT secondary to ciga-
rette smoke [12]. In the current study, pre-incubation with roflu-
milast N-oxide concentration-dependently rescued from a CSE
(2.5%) induced loss in intracellular cAMP levels after 72 h of
exposure. In fact, at 2 nM the PDE4 inhibitor reversed compromised
cAMP levels to baseline and even higher levels were found at 1 mM
concentration (Fig. 3A). When well-differentiated HBEC were
exposed to CSE 2.5% over 30 min intracellular ROS increased that
was concentration-dependently reduced by roflumilast N-oxide at
2 nM and 1 mM (Fig. 3D, E). Long-term stimulation of well-
differentiated HBEC with CSE 2.5% for 72 h resulted in an increase
in NOX4 mRNA and protein that both were curbed by roflumilast
N-oxide (Fig. 3B and C).
As previously reported cigarette smokemay increase the release
of TGF-b1 and then result in ERK1/2 and Smad3 phosphorylation
playing a key role in CSE-induced EMT [12]. We now report thatFig. 4. Roflumilast N-oxide (RNO) inhibits cigarette smoke extract (CSE)-induced TGF-b1 se
epithelial cells (HBECs). Differentiated HBECs were incubated with RNO for 30 min before C
were extracted to quantify (A) TGF-b1 release, (B) ERK1/2 phosphorylation and (C) Smad
expressed as the ratio to total ERK1/2 and Smad3 respectively and normalized to the vehic
smoker population) experiments per condition. Two-way ANOVA followed by post hoc Bon
Please cite this article in press as: Milara J, et al., Roflumilast N-oxide
cigarette smoke in smokers with COPD, Pulmonary Pharmacology & Theroflumilast N-oxide reduced this increase in TGF-b1 release and
that of ERK1/2 and Smad3 phosphorylation secondary to CSE (2.5%,
72 h) (Fig. 4A, B and 4C).
3.3. EMT markers in primary HBECs from smokers and COPD and
lung function
Previously we have shown enhanced mesenchymal yet
compromised epithelial markers of EMT in primary cultured hu-
man bronchial epithelial cells from smokers or COPD if compared
with non-smokers, non-COPD [12]. Here it has been explored
whethermarkers of EMTmay relate to lung function (FEV1 (post), %
of predicted). To this end, human bronchial epithelial cells obtained
from small bronchi (<2 mm of internal diameter) of smokers
(n ¼ 8) and COPD patients (current smokers) (n ¼ 9) (who were
under lung surgery for lung carcinoma) where analysed for thecretion and phosphorylation of ERK1/2 and Smad3 in differentiated human bronchial
SE (2.5%) stimulation for 72 h. Cell culture supernatant (A) and protein content (B, C)
3 phosphorylation. (B, C) Phospho-Smad3 and phospho-ERK1/2 protein levels were
le control group. Results are expressed as means  SD of n ¼ 3 (two to four cell non-




















inhibits bronchial epithelial to mesenchymal transition induced by
rapeutics (2014), http://dx.doi.org/10.1016/j.pupt.2014.02.001
Fig. 5. The expression of epithelial to mesenchymal transition markers is correlated with lung function. Primary human bronchial epithelial cells (HBECs) from smokers (n ¼ 9) and
COPD patients (n ¼ 9) were isolated from small bronchi and lysed to extract proteins. Protein expression of mesenchymal markers (A) a-SMA, (B) vimentin, (C) collagen type I (col
type I) and (D) NOX4; Epithelial markers (E) E-cadherin, (F) ZO-1; intracellular signals (G) phospho-ERK1/2 and (H) phospho-Smad3 was measured (Zeptosens). Data are expressed
as the ratio of target protein to house-keeping b-actin, normalized to a control group (non smoker, non COPD; Table 1). Phospho-Smad3 and phospho-ERK1/2 protein levels were
expressed as the ratio to total Smad 3 and ERK1/2, normalized to a control group (non smoker, non COPD; Table 1), respectively. Data was correlated with %FEV1 lung function.
Spearman (r) correlation analysis. P < 0.05 value showed significant correlation.



































































































































YPUPT1357_proof ■ 13 February 2014 ■ 7/11expression of EMT markers. Clinical data of the investigated cohort
are depicted in Table 1.
a-SMA, vimentin and collagen type I protein in primary HBECs
were inversely correlated with %FEV1 (Fig. 5A, B and 5C; Spearman
r ¼ 0.60, r ¼ 0.54 and r ¼ 0.72 respectively, and P ¼ 0.010,
P ¼ 0.020 and P ¼ 0.002 respectively). E-cadherin was directly
correlated with %FEV1 (Fig. 5E; Spearman r¼ 0.62; P¼ 0.007). ZO-1
expression and NOX4 were not correlated with %FEV1. Both,
phospho-ERK1/2 and phospho-Smad3 were inversely correlated
with %FEV1 (Fig. 5G and H; Spearman r ¼ 0.55, r ¼ 0.50 and
P ¼ 0.020, P ¼ 0.048 respectively).
3.4. In vitro treatment of primary HBECs from smokers and COPD
patients with roflumilast N-oxide attenuates EMT markers
Finally it was asked whether in vitro incubation of human
bronchial epithelial cells from current smokers with and without
COPD compared to non-smokers, non COPD with roflumilast
N-oxide (2 nM) or vehicle over 24 h influenced the expression of
EMT markers. In HBEC of current smokers with or without COPD,
roflumilast N-oxide significantly reduced the mRNA expression of
a-SMA, vimentin and collagen type I as mesenchymal markers and
NOX4 but increased the expression of the epithelial markers E-
cadherin and ZO-1 compared to vehicle (Fig. 6 CeF). In contrast, the
PDE4 inhibitor did not significantly influence these mRNA tran-
scripts in HBEC from non smokers, non COPD (Fig. 6 A, B). There
were no differences in the proportion of apoptotic (or necrotic) cells
between non-smoking healthy controls, smokers without COPD
and smokers with COPD (Fig. 7).
4. Discussion
The current study demonstrates for the first time that roflumi-
last N-oxide, a PDE4 inhibitor mitigates epithelial to mesenchymal
transition (EMT) elicited by cigarette smoke extract in well-
differentiated human bronchial epithelial cells (HBEC) in vitro.Please cite this article in press as: Milara J, et al., Roflumilast N-oxide
cigarette smoke in smokers with COPD, Pulmonary Pharmacology & TheAdding roflumilast N-oxide at 2 nM (a concentration corresponding
to plasma concentrations of this active metabolite following
repeated dosing of roflumilast at its clinically approved dose of
500 mg/d per os), to HBEC primary cultures from smokers with and
without COPD (but not from non-smokers, non COPD) attenuated
EMT markers. Finally, markers of EMT correlated to FEV1 (% of
predicted) in smokers with and without COPD. Collectively,
addressing EMT could hypothetically represent another mecha-
nistic pathway in the mode of action of the PDE4 inhibitor roflu-
milast to target COPD pathophysiology [37,38].
EMT as part of the airway remodelling in COPD patients has
recently been studied by our group and others [12,39,40]. Indeed,
one may postulate that EMT is initiated in small bronchi of smokers
and patients with COPD by chronic oxidative stress from cigarette
smoking. Hypothetically, transition of basal bronchial epithelial
cells into a mesenchymal, myofibroblast-like phenotype may allow
their migration to the smooth muscle layer, increases peri-
bronchiolar fibrosis and bronchial smooth muscle thickness, finally
supporting small bronchi narrowing and airway resistance. In our
previous study immunohistochemical analyses in small airways
revealed that in comparison to non-smokers, non-COPD mesen-
chymal markers of EMT are increased in basal bronchial epithelial
cells of smokers and patients with COPD while epithelial markers
are decreased [12]. Furthermore, primary HBECs isolated from
smokers and COPD patients maintained such increased mesen-
chymal and decreased epithelial cell markers [12]. Complementing
these findings we now observed that across the subjects (current
smokers with and without COPD) included in this study protein
expression of EMT mesenchymal markers such as aSMA or type I
collagen in primary HBEC cultures may inversely correlate to their
FEV1 (% of predicted) while there was a direct correlation to the
epithelial marker E-cadherin. A limitation may be that the evalu-
ation included subjects with mostly mild (COPD) or no (smoker)
impairment of lung function. In this context, it has recently been
confirmed that EMT occurs likely as an early response to smoking
[41]. Furthermore, EMT can also be observed in small bronchi ofinhibits bronchial epithelial to mesenchymal transition induced by
rapeutics (2014), http://dx.doi.org/10.1016/j.pupt.2014.02.001
Fig. 6. Roflumilast N-oxide (RNO) decreased mesenchymal markers and increased epithelial markers in primary human bronchial epithelial cells (HBECs) isolated from small
bronchi of smokers and COPD patients. Human small bronchi from non-smokers (n ¼ 3), smokers (n ¼ 4) and smokers with COPD (n ¼ 6) patients were plated with the epithelial
cell layer in contact with culture plates. After approximately 10 days when HBECs were observed around bronchi at about confluency bronchial tissue was removed and primary
HBECs were incubated with vehicle or RNO (2 nM) for 24 h in cells from non-smokers, non COPD (A, B) or smokers without (C, D) or with COPD (E, F). Total mRNA was isolated and
quantified by real-time PCR with appropriate primers. Results frommRNAmeasurements of the mesenchymal markers a-SMA, vimentin, collagen type I (col type I) or NOX4, as well
as the epithelial markers E-cadherin or ZO-1 are shown. Data are expressed as the ratio to GAPDH for mRNA levels and normalized to the vehicle group. Data are presented as a box
and whisker plot with median, IQR and minimum and maximum values. “P” exact values were obtained following ManneWhitney U test.



































































































































YPUPT1357_proof ■ 13 February 2014 ■ 8/11more severe COPD (GOLD stage 3) [31] reflecting a sustained EMT
remodelling process during the progression of COPD.
Previously we described that both an increased expression of
themesenchymal EMTmarkers aSMA, vimentin and collagen type I
and a reduction of the epithelial EMTmarkers E-cadherin and ZO-1
following exposure of well-differentiated HBECs to CSE (2.5%) overPlease cite this article in press as: Milara J, et al., Roflumilast N-oxide
cigarette smoke in smokers with COPD, Pulmonary Pharmacology & The72 h was reversed by the cAMP analogue dibutyryl cAMP (1 mM).
Given the earlier observation that CSE (however at 10% and over
24 h) enhanced PDE4 activity and expression (PDE4B) in well-
differentiated HBEC along with the finding that roflumilast N-ox-
ide reversed a potentially resulting CSE-induced loss in cellular
cAMP content it was reasonable to assume that the PDE4 inhibitorinhibits bronchial epithelial to mesenchymal transition induced by
rapeutics (2014), http://dx.doi.org/10.1016/j.pupt.2014.02.001
Fig. 7. Analysis of spontaneous apoptosis/necrosis in human primary bronchial epithelial cells (HBECs) from healthy non-smokers, smokers and patients with COPD. Primary human
bronchial epithelial cells from healthy non-smokers (n ¼ 3), smokers (n ¼ 4) and smokers with COPD (n ¼ 4) were isolated and cultured without further passaging. When cells
reached confluency, they were washed three times and labeled with annexin V-FITC and propidium iodide for 15 min. Annexin Vþ/PI- (apoptotic) and Annexin Vþ/PIþ (necrotic)
cells were counted (epifluorescence microscope in a total of six fields per condition) and results expressed as percentage of total cells. Results are the mean  SD of n ¼ 3 ex-
periments from three different patients. Scale bar: 50 mm.











































































































YPUPT1357_proof ■ 13 February 2014 ■ 9/11was capable to curb CSE-induced EMT in these cells. While in
general, the ability of PDE4 inhibitors to mitigate EMT has already
been demonstrated by others with human alveolar adenocarci-
noma A549 cells and TGFb1 as stimulus [16], the novelty in the
current study is based on the use of well-differentiated HBECs
obtained from aireliquid interface culture considered to well
reflect the composition of the pseudo-stratified human bronchial
epithelium and CSE extract to imitate smoking as a key risk factor in
COPD directly targeting bronchial epithelium of those who smoke.
Further, roflumilast N-oxide as the active metabolite of roflumilast
in use for the treatment of COPD served as the PDE4 inhibitor not
only at 1 mMwhere PDE4 is completely and selectively inhibited but
also at 2 nM which corresponds to plasma concentrations in man
(unbound to protein) following repeated, once daily dosing of
roflumilast at the approved dose of 500 mg/d. In line with its ability
to fully restore the loss in cellular cAMP following CSE attributed to
inhibition of PDE4, roflumilast N-oxide at 2 nM revealed as rather
effective to reverse CSE-induced EMT based on the mRNA and
protein expression of mesenchymal and epithelial markers. ForTable 1
Clinical features of patients. % pred, % predicted; COPD, chronic obstructive pul-
monary disease (current smokers); FEV1, forced expiratory volume in 1 s; FVC,
forced vital capacity; Pack-yr, 1 year smoking 20 cigarettes-day; PaO2, oxygen ten-
sion in arterial blood; PaCO2, carbon dioxide tension in arterial blood; Post, post-
bronchodilator; Pre, pre-bronchodilator; LABA, long-acting b2-adrenoceptor ago-








Sex (female/male) 4/6 2/6 3/6
Age (years) 65 [58e77] 67 [58e72] 66 [56e71]
Tobacco consumption, pack-year 0 40 [35e47] 37 [32e43]
FEV1 (pre), % predicted 98 [96e102] 92 [90e96] 60 [51e69]
FVC (pre), % predicted 101 [96e105] 96 [92e101] 83 [87e99]
FEV1/FVC (pre) % 94 [92e100] 84 [79e92] 56 [52e61]
FEV1 (post), % predicted 101 [98e105] 94 [90e97] 68 [52e70]
FVC (post), % predicted 103 [95e106] 97 [92e102] 90[87e100]
FEV1/FVC (post) % 96 [92e102] 87 [78e91] 60 [50e65]
PaO2, mmHg 92 [86e94] 88 [85e94] 80 [76e87]
PaCO2 mmHg 38 [37e41] 36 [34e40] 42 [38e44]
Subjects on inhaled steroids, (N) 0 0 2
Subjects on theophyllines, (N) 0 0 0
Subjects on LABA, (N) 0 0 6

























Please cite this article in press as: Milara J, et al., Roflumilast N-oxide
cigarette smoke in smokers with COPD, Pulmonary Pharmacology & Thecomparison the IC50 values for roflumilast N-oxide to inhibit hu-
man PDE4B2, D3 and A4 splice variants expressed in well-
differentiated human bronchial epithelial cells [12] are at 1.1, 0.8
and 2.3 nM respectively [19]. As cellular effects of a PDE4 inhibitor
are contingent on the extent of cAMP synthesis amongst others one
may speculate that a considerable adenylyl cyclase activity at
baseline or enhanced by autocrine mediators may enable roflumi-
last N-oxide (2 nM) to reduce CSE-induced EMT. Notably, though, in
contrast to effects on mesenchymal EMT marker transcripts and
proteins where the increase by CSE was largely abolished with
roflumilast N-oxide at 2 nM this concentration of the PDE4 inhib-
itor did only partially (40e45%) reverse the CSE-induced loss in E-
cadherin and ZO-1 epithelial marker transcripts while their protein
levels were fully restored. This may indicate that E-cadherin and
ZO-1 transcripts versus proteins are differentially regulated by
cAMP. In fact it has been shown that TGFb1-induced E-cadherin loss
representing an early event in EMT may occur secondary to MMP-
induced proteolytic E-cadherin disruption in renal tubular epithe-
lial cells [42].
How may roflumilast N-oxide by enhancing cellular cAMP
alleviate CSE-induced EMT in well-differentiated HBECs? Previ-
ously, we observed that the loss in E-cadherin and ZO-1 and the
increase in aSMA, collagen I and vimentin following exposure of
well-differentiated HBEC to CSE are all reversed by a neutralizing
antibody to TGFb1 [12]. In fact, exposure of HBEC to CSE (2.5%) over
72 h resulted in an increase in TGFb1 into the culture medium. Such
increase was abolished by roflumilast N-oxide at both 2 nM and
1 mM concentrations along with down-stream signalling exempli-
fied by the reduced phosphorylation of ERK1/2 and Smad3.
Reactive oxygen species (ROS) are intimately related to EMT and
an increase in cellular cAMP is well capable to mitigate stimulus
(e.g. TGFb1, CSE)-induced cellular ROS formation. For example in
renal tubular epithelial cell lines TGFb1-induced a rapid increase in
ROS and anti-oxidants (such as apocynin, diphenyliodonium,
rotenone, N-acetylcysteine) were all able to prevent EMT [47]. In
human alveolar epithelial A549 cells TGFb1 enhanced ROS forma-
tion in parallel to the occurance of EMT [16]. Recent work from this
laboratory [12] documented in well-differentiated HBECs stimu-
lated with CSE (2.5%) (i) a rapid (at 30 min) increase in intracellular
ROS (assessed as DCF fluorescence), (ii) a later (measured at 72 h)
up-regulation of NOX4 mRNA and protein, (iii) a prevention of EMT
based on mesenchymal and epidermal markers with the antioxi-








































































































































YPUPT1357_proof ■ 13 February 2014 ■ 10/11increase in cAMP by prostaglandin E2, forskolin or the non-specific
PDE inhibitor IBMX largely abolished the TGFb1-induced increase
in the rapid (30 min) accumulation of intracellular ROS and EMT
[48]. Further, TGFb1 induced ROS in A549 cells (24 h) was partially
reduced by rolipram that curbs EMT. In well-differentiated HBECs
we previously found that dibutyryl cAMP as well as roflumilast
N-oxide (1 mM, 2 nM) prevented the increment in ROS accumu-
lating following a 30 min exposure to CSE [12,27] that was
confirmed in the current work. Whilst the mechanistic background
for the inhibition of the rapid, stimulus-triggered ROS formation by
the PDE4 inhibitor remains to be explored the notionmay be raised
that this effect is caused by an inhibition of NOX2 or NOX1 as-
sembly (well expressed in human bronchial epithelial cells [27])
perhaps by reducing active (GTP-bound) Rac1 [49].
Expanding on our previous findings that exposing well-
differentiated HBECs to CSE over longer time periods (i) enhances
NOX1 and 2 transcripts which is suppressed by roflumilast N-oxide
[27], (ii) increases NOX4 transcripts and protein which is reduced
by dibutyryl cAMP [12] it has now been shown that roflumilast
N-oxide curbed NOX4 expression. However, the functional role of
the NOX isoenzymes in CSE-induced EMT remains to be dissected.
NOX4 represents a constitutively active, mainly hydrogen peroxide
producing NADPH oxidase that is independent from cytosolic
proteins (such as p67phox) for its operation (hence, from rac1) with
its activity largely regulated by expression. NOX4 is functionally
involved in myofibroblast transition [50] and up-regulated in IPF
lung fibroblasts [51]. It has been described that genetic knock-down
of NOX4 reduced TGFb1-induced fibronectin expression in human
breast epithelial cells that was considered as a marker of EMT [52].
On the other hand, NOX4 was dispensable for TGFb1-induced EMT
in hepatocytes [53].
Taken together, an inhibition of CSE-induced, autocrinously
acting TGFb1, likely themost prominent inductor of EMTand that of
ROS could explain why roflumilast N-oxide prevents well-
differentiated HBEC from CSE-induced EMT. Indeed, emanating
from an increase in cAMP a PDE4 inhibitor would be capable to
suppress ROS at least at three different levels (i) by a short-term
reduction of NOX1 or NOX2 activity likely caused by reduction of
active (GTP bound) Rac1, (ii) by long term inhibition of NADPH
oxidase expression (e.g. NOX1, 2, 4), (iii) by improving the anti-
oxidative armamentarium through enhancing Nrf2 [54,55].
Hypothetically, such mechanisms may also explain why roflu-
milast N-oxide has been able to alleviate enhanced mesenchymal
and reduced epithelial markers of EMT maintained in primary
cultured HBEC from smokers with or without COPD, while not
affecting these measures in cultures from non-smokers, non COPD
subjects. Of interest in this context it was recently shown that
PGE2 acting via the EP2/EP4-cAMP signalling pathway might
reverse established lung myofibroblast differentiation to TGFb1
[56].
In parallel to EMT, CSE may entail other effects such as epithelial
cell apoptosis/necrosis which largely depend of the concentration
and time of exposure. Thus, high concentrations of CSE (for
example 10% over 24 h) may induce bronchial epithelial cell
apoptosis [43] while low concentrations do not show such effect
[44,45]. In our in vitro model exposure of well-differentiated hu-
man bronchial epithelial cells to CSE at 2.5% over a period of 72 h
about doubled apoptosis at medium control conditions (to about
35% or total cells). Roflumilast N-oxide partly reduced the incre-
ment in apoptosis secondary to CSE indicating to a protective effect
in parallel to the inhibition of EMT. A common denominator of
these findings may be that CSE is reported to enhance ER stress
resulting in apoptosis or EMT contingent on the experimental
conditions in airway epithelial cells [57]. Necrosis was negligible
and unchanged under the explored conditions.Please cite this article in press as: Milara J, et al., Roflumilast N-oxide
cigarette smoke in smokers with COPD, Pulmonary Pharmacology & The5. Conclusions
Roflumilast N-oxide, a PDE4 inhibitor protects from EMT
emanating from exposing well-differentiated HBECs to cigarette
smoke extracts (2.5%) over 72 h in vitro. Reducing the burden of
reactive oxygen species and suppressing the release of autocri-
nously acting TGFb1 from the HBEC cultures may account for these
protective effects. These effects of roflumilast N-oxide were also
found at 2 nM, a concentration corresponding to plasma concen-
trations following clinical dosing of roflumilast and were repro-
duced in primary HBECs from smokers and COPD. Finally, prior
observations that EMT markers were enhanced in smokers and
patients with COPD were extended by showing their correlation to
FEV1 (% of predicted).Conflict of interest statement
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